Palliative Care for Non-Malignant Diseases (COMPASS Trial)

Liver Cirrhosis Clinical Trial

— COMPASS  

Official title:

The Creation of Models for Palliative Assessments to Support Severe Illness (COMPASS) Investigation: Testing Early and Ongoing Implementation of Palliative Care for Incurable Non-malignant Diseases

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03022630
• Other study ID #: 160746
• Status: Terminated
• Phase: N/A
• Start date: February 6, 2017
• Est. completion date: June 21, 2018

Study information

• Verified date: August 2019
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate, through a randomized controlled trial, the impact of integrated comprehensive palliative care services on time to first hospital readmission and other hospital utilization outcomes, quality of life, and patient/caregiver outcomes. The intervention includes comprehensive, standardized palliative care services for adult hepatology cirrhosis patients for which prognosis is poor.

Description:

Palliative care is specialized medical care focused on providing patients with relief from the symptoms, pain, and stress of serious or life-limiting illness, regardless of diagnosis, by anticipating, preventing, and treating suffering. Palliative care aims to provide patients and their families with services to help patients make the best possible medical decisions in the face of serious illness. Unfortunately it is often thought to be synonymous with hospice care and therefore underutilized as a part of standard care. Patients with chronic liver disease or cirrhosis may be a particularly underserved population for palliative care, as palliative care may be disregarded until hope of liver transplantation is lost.

Study Description:

• Adult patients admitted to Vanderbilt University Medical Center with cirrhotic advanced liver disease and poor prognosis will be randomized to receive either usual hepatic care or usual hepatic care with comprehensive palliative care services.

• Participants randomized to the intervention arm will receive patient-friendly informational materials, a comprehensive initial palliative care consultation, and follow-up consultations while inpatient. After discharge from hospital, follow-up consults will occur via telephone contact. Telephone contacts will occur on a flexible schedule based on needs and wishes of the participant at a minimum frequency of one contact per month.

• Participants will receive the palliative care intervention for at least 1 year after randomization to the intervention arm or until death.

• Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a meeting is requested by the patient, the family, or treating physician. These consultations include the same palliative care services as the intervention arm, excluding the telephone follow-up consultations.

• All participants will complete quality of life, mood, and satisfaction with care assessments at specified time points for 1 year after randomization or until death. Optional caregiver participation includes completion of satisfaction with care assessments.

Specific aims include:

1. Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on time to first hospital readmission within 1-year post randomization.

2. Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on other hospital utilization, including days alive out of hospital within 6- months post randomization, total days in hospital (and ICU) within 1-year post randomization, number and cost of hospital admissions within 1-year post randomization, median length of stay per admission, transfers and time to hospice placement, and survival within 1-year post randomization.

3. Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on qualify of life.

4. Assess the impact of systematic, comprehensive palliative care services compared to usual hepatic care on patient/caregiver satisfaction.

5. Evaluate the fidelity of the palliative care intervention and assess the generalizability of implementing a large-scale Palliative Care program.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 63
• Est. completion date: June 21, 2018
• Est. primary completion date: June 21, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Inpatient at Vanderbilt University Medical Center with advanced cirrhotic liver disease, whose treating hepatologist indicates a 'No' response to the question, "Would you be surprised if this patient died within 1 year?"

Exclusion Criteria:

• Age < 18 years

• Receipt of liver transplant at the time of potential enrollment

• Inability to give written informed consent (patient or surrogate decision-maker)

• Inability to respond to questions in English

• Treating hepatologist denies permission to enroll

• Receiving hepatology care at non-Vanderbilt sites (to ensure appropriate follow-up)

Related Conditions & MeSH terms

• Fatty Liver
• Fibrosis
• Liver Cirrhosis
• Liver Diseases
• NASH (Non-Alcoholic Steatohepatitis)
• Non-alcoholic Fatty Liver Disease

Intervention

Other:
• Comprehensive Palliative Care services
Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
• Usual hepatic care
Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to First Hospital Readmission Within 6 Months Post-randomization	Assess the impact of palliative care services on time to first hospital readmission.; Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Days Alive Out of Hospital	Days alive out of hospital from randomization to 6 months post randomization compared across arms.; Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Total Days in Hospital	Total days in hospital from randomization to 6 months post randomization compared across arms Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Total Days in ICU	Total days in ICU from randomization to 6 months post randomization compared across arms.; Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Number of Hospital Readmissions	Number of hospital readmissions from randomization to 6 months post randomization compared across arms.; Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Median Length of Hospital Stay Per Admission	Median length of hospital stay per admission from randomization to 6 months post randomization compared across arms.; Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Hospice Referral	Number of transfers to hospice within 6 months post randomization compared across arms.; Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Time to Hospice Placement	Number of days from hospice referral to time to hospice placement. Time frame was changed from 1 year to 6 months due to early termination. There are only 3 patients with a hospice admission date that is after baseline discharge, all of whom are from the control group. The remaining patients with hospice referral but are missing a hospice admission date due to death before hospice admission. Therefore, it is not feasible to calculate any statistics.	6 months post-randomization
Secondary	Change in Chronic Liver Disease Questionnaire (CLDQ)	Change in liver disease-related quality of life: The CLDQ is a 29-item questionnaire measuring 6 domains. Item scores range from 1 to 7 with higher scores indicating better quality of life. The total score can range from 29 to 203 with a score of 1 meaning the symptom being assessed is "present always" while a score of 7 means the symptom is "never present". Therefore, a higher score corresponds to a better quality of life while a lower score corresponds to a worse quality of life. The questions in each domain have a range of factor loads indicative of their impact, and a clinically important difference is defined as a score change of 0.5.; Time frame was changed from 1 year to 6 months due to early termination.	Change from baseline over 6 months post-randomization
Secondary	Change in EQ-5D-5L	Change in generic health status: The EQ-5D-5L is a 5-item questionnaire with responses ranging from absence of symptom to extreme experience of the symptom. This scale is numbered from 0 to 100. 100 means the best health you can imagine and 0 means the worst health you can imagine.; Time frame was changed from 1 year to 6 months due to early termination.	Change from baseline over 6 months post-randomization
Secondary	Change in PROMIS Emotional Distress - Anxiety - Short Form 4a	Change in mood (anxiety): The PROMIS Emotional Distress - Anxiety - Short Form 4a contains 4 items that measure anxiety on a 5-point Likert scale with higher scores indicating increased symptomatology. The raw score can range from 4 to 20 which converts to a t-score range of 40.3 to 81.6.; Time frame was changed from 1 year to 6 months due to early termination.	Change from baseline over 6 months post-randomization
Secondary	Change in PROMIS Emotional Distress - Depression - Short Form 4a	Change in mood (depression): The PROMIS Emotional Distress - Depression - Short Form 4a contains 4 items that measure depression on a 5-point Likert scale with higher scores indicating increased symptomatology. The raw score ranges from 4 to 20 which converts to a t-score range of 41.0 to 79.4.; Time frame was changed from 1 year to 6 months due to early termination.	Change from baseline over 6 months post-randomization
Secondary	Change in Satisfaction With Care (Quality of End-of-Life Care: Questionnaire for Patient)	Change in patient satisfaction with care: The Quality of End-of-Life Care: Questionnaire for Patient is an 11-item questionnaire, with items scored on a 10-point Likert type scale with higher scores indicating better satisfaction with care. The score can range from 0 to 110.; Time frame was changed from 1 year to 6 months due to early termination.	Change from baseline over 6 months post-randomization
Secondary	Change in Kingston Caregiver Stress Scale	The Kingston Caregiver Stress Scale will be used to measure caregiver stress. The KCSS is designed to measure stress experienced by lay caregivers, not institutional staff, and was designed to monitor change in an individuals stress over time. Ten items are grouped into three categories: care giving, family, and financial issues. Scores can range from 10 to 50. Lower scores indicate less stress and higher scores indicate high stress.; Time frame was changed from 1 year to 6 months due to early termination.	Change from baseline over 6 months post-randomization
Secondary	Change in Satisfaction With Care (Quality of End-of-Life Care: Questionnaire for Patient Adapted for Caregiver)	Change in caregiver satisfaction with care: The Quality of End-of-Life Care: Questionnaire for Patient item wording was modified to apply to caregivers. The questionnaire is an 11-item questionnaire, with items scored on a 10-point Likert type scale with higher scores indicating better quality of care. The score can range from 0 to 110.; Time frame was changed from 1 year to 6 months due to early termination.	Change from baseline over 6 months post-randomization
Secondary	Liver Transplant Status	Number of deferred, listed, and declined listing for liver transplant compared across arms.; Time frame was changed from 1 year to 6 months due to early termination. Liver transplant status data was not obtained.	6 months post-randomization
Secondary	Model for End-Stage Liver Disease (MELD) Score	Baseline MELD score compared across arms. MELD score ranks the participants degree of sickness and indicates how much the participant needs a liver transplant. The score ranges from 6-40. The higher the number the more urgent the need for a transplant.	Baseline
Secondary	Completed Liver Transplants	Number of patients with completed liver transplants compared across arms. Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Physical Symptoms	Number of documented physical symptoms (ascites, variceal bleeding, encephalopathy, etc.) compared across arms.; Time frame was changed from 1 year to 6 months due to early termination. Physical symptom data was not obtained.	6 months post-randomization
Secondary	Presence of Advance Directives	Percentage of patients with documented advance care directives compared across arms.; Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Survival	Survival rate compared across arms. Time frame was changed from 1 year to 6 months due to early termination.	6 months post-randomization
Secondary	Provider Satisfaction	The "ICU Provider Satisfaction Survey with the Palliative Care Program:Veterans Affairs of Ann Arbor" instrument is available online and has been modified for the current study by removing the 'ICU' reference and revising 'pain' to symptoms more relevant to the current population. The survey includes 7-item questionnaire, with items scored on a 5-point Likert type scale with higher scores indicating better provider satisfaction. The score can range from 0 to 35.; Time frame was changed due to early termination. Data was not collected.	Change from Baseline to study closeout.